Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy

BACKGROUND: Erdheim–Chester disease (ECD), a rare inflammatory myeloid neoplasm, is known to be fundamentally reliant on the constitutive activation of the MAPK signaling pathway in the majority of patients. Consequently, inhibition of the V600E-mutant BRAF kinase has proven to be a safe and efficac...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurooncol Adv
Autors principals: Mazor, Roei D, Weissman, Ran, Luckman, Judith, Domachevsky, Liran, Diamond, Eli L, Abdel-Wahab, Omar, Shapira, Shirley, Hershkovitz-Rokah, Oshrat, Groshar, David, Shpilberg, Ofer
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Clinical Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7212923/
https://ncbi.nlm.nih.gov/pubmed/32642685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa024
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars